The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer

Oncology Reports

Volumn 18, Issue 1, 2007, Pages 113-119

  Koda, Mariusz ^a   Sulkowska, Mariola ^a   Kanczuga Koda, Luiza ^a   Tomaszewski, Jakub ^a   Kucharczuk, Waldemar ^a   Lesniewicz, Tomasz ^a   Cymek, Slawomir ^a   Sulkowski, Stanislaw ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Apoptosis; Bak; Bcl 2; Breast cancer; Ki 67; Lymph node metastasis; Preoperative chemotherapy; Primary tumor; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; BAK1 PROTEIN, HUMAN; CMF REGIMEN; CYCLOPHOSPHAMIDE; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROTEIN BAK; PROTEIN BCL 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; PREOPERATIVE CARE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 34548050225     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.1.113     Document Type: Article

References (28)

1. Sierra A, Castellsague X, Escobedo A, Lloveras B, Garcia-Ramirez M, Moreno A and Fabra A: Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. Int J Cancer 89: 142-147, 2000. (Pubitemid 30185922)
2. Koda M, Przystupa W, Jarzabek K, Wincewicz A, Kanczuga-Koda L, Wincewicz A, Tomaszewski J, Sulkowska M, Wolczynski S and Sulkowski S: Expression of insulin-like growth factor-I receptor, estrogen receptor α, Bcl-2 and Bax proteins in human breast cancer. Oncol Rep 14: 93-98, 2005.
3. Koda M, Kanczuga-Koda L, Reszec J, Sulkowska M, Famulski W, Baltaziak M, Kisielewski W and Sulkowski S: Expression of the apoptotic markers in normal breast epithelium, benign mammary dysplasia and in breast cancer. Folia Morphol 63: 337-341, 2004. (Pubitemid 39263796)
4. Kanczuga-Koda L, Sulkowski S, Tomaszewski J, Koda M, Sulkowska M, Przystupa W, Golaszewska J and Baltaziak M: Connexins 26 and 43 correlate with Bak, but not with Bcl-2 protein in breast cancer. Oncol Rep 14: 325-329, 2005.
5. Eguchi H, Suga K, Saji H, Toi M, Nakachi K and Hayashi SI: Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to proapoptotic Bak gene. Cell Death Differ 7: 439-446, 2000. (Pubitemid 30255712)
6. Rochaix P, Krajewski S, Reed JC, Bonnet F, Voigt JJ and Brousset P: In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis. J Pathol 187: 410-415, 1999. (Pubitemid 29118271)
7. Alison MR: Assessing cellular proliferation: what's worth measuring? Hum Exp Toxicol 14: 935-944, 1995.
8. Jansen RL, Hupperets PS, Arends JW, Joosten-Achjanie SR, Volovics A, Schouten HC and Hillen HF: MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78: 460-465, 1998. (Pubitemid 28360632)
9. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JF, Blamey RW and Ellis IO: Assessment of the new proliferation marker MIB-1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71: 146-149, 1995.
10. Koda M, Sulkowski S, Garofalo C, Kanczuga-Koda L, Sulkowska M and Surmacz E: Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors α and β. Horm Metab Res 35: 794-801, 2003. (Pubitemid 38058185)
11. Koda M, Sulkowski S, Kanczuga-Koda L, Surmacz E and Sulkowska M: Expression of ERα, ERβ and Ki-67 in primary tumors and lymph node metastases in breast cancer. Oncol Rep 11: 753-759, 2004.
12. Koda M, Sulkowska M, Kanczuga-Koda L and Sulkowski S: Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases. J Clin Pathol 58: 645-649, 2005. (Pubitemid 40814028)
13. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S and Surmacz E: Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 12: 1447-1453, 2006.
14. Kanczuga-Koda L, Sulkowski S, Lenczewski A, Koda M, Wincewicz A, Baltaziak M and Sulkowska M: Increased expression of connexins 26 and 43 in lymph node metastases of breast cancer. J Clin Pathol 59: 429-433, 2006.
15. Koda M, Lenczewski A, Sulkowska M, Kanczuga-Koda L, Wincewicz A, Tomaszewski J and Sulkowski S: The effect of chemotherapy on status of estrogen receptors in primary tumors and lymph node metastases of human ductal breast cancer. Oncol Rep 17: 385-391, 2007.
16. Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD and Millis RR: The effects of chemotherapy on morphology, cellular proliferation, and oncoprotein expression in primary breast carcinoma. Br J Cancer 70: 335-341, 1994. (Pubitemid 24247160)
17. Aktepe F, Kapucuoglu N and Pak I: The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology 29: 63-67, 1996. (Pubitemid 26232524)
18. Teixeira MR, Pandis N, Bardi G, Andersen JA and Heim S: Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res 56: 855-859, 1996. (Pubitemid 26055477)
19. Teixeira MR, Tsarouha H, Kraggerud SM, Pandis N, Dimitriadis E, Andersen JA, Lothe RA and Heim S: Evaluation of breast cancer polyclonality by combined chromosome banding and comparative genomic hybridization analysis. Neoplasia 3: 204-214, 2001. (Pubitemid 32747569)
20. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A, Bolsi G, Allevi G, Generali D, Betri E, Bertoli G, Alquati P and Dogliotti L: Relationship between tumour shrinkage and reduction in Ki-67 expression after primary chemotherapy in human breast cancer. Br J Cancer 85: 1106-1112, 2001. (Pubitemid 33052307)
21. Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC and Dowsett M: Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat 53: 51-59, 1999. (Pubitemid 29123619)
22. Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R and Filipits M: Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 78: 97-103, 2003. (Pubitemid 36223022)
23. Sato T, Kijima H, Suto A, Sato S, Terasaki-Fukuzawa Y, Yoshida H, Shimbori M, Onoda N, Osamura RY and Takeshita T: Bcl-2 expression in breast cancer is down-regulated by transarterial administration of chemotherapeutic agents. Oncol Rep 8: 1019-1022, 2001. (Pubitemid 33758161)
24. Koda M, Jarzabek K, Kanczuga-Koda L, Przystupa W, Tomaszewski J, Sulkowska M, Wolczynski S and Sulkowski S: Comparative studies of Ki-67 expression between the primary tumor and breast cancer metastases to regional lymph nodes. Ginekol Pol 74: 754-760, 2003.
25. O'Reilly LA, Huang DC and Strasser A: The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 15: 6979-6990, 1996. (Pubitemid 27023269)
26. Furth PA, Bar-Peled U, Li M, Lewis A, Laucirica R, Jager R, Weiher H and Russell RG: Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model. Oncogene 18: 6589-6596, 1999.
27. Reed JC: Mechanisms of apoptosis. Am J Pathol 157: 1415-1430, 2000.
28. Sjöström J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Wist E, Valvere V, Takayama S, Reed JC and Saksela E: The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 8: 811-816, 2002. (Pubitemid 34742112)